Genmab throws in the towel – won't contest royalties ruling

The Danish biotech firm won’t be seeking a review of its arbitration case against Janssen, which Genmab lost at the beginning of April.
Photo: Tuala Hjarnø / Genmab / PR
Photo: Tuala Hjarnø / Genmab / PR
by andreas lønstrup, translated by daniel pedersen

Genmab has decided to let the royalties dispute over multiple myeloma treatment Darzalex with its collaboration partner Janssen lie.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading